Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway

On February 17, AI pharmaceutical company insilico medicine announced that it had nominated preclinical candidate compounds targeting qpctl for innovative tumor immunotherapy using its self-developed artificial intelligence platform. It is worth mentioning that this is the first important milestone reached in the strategic cooperation between silicon smart and Fosun Pharmaceutical. Silicon smart and Fosun Pharmaceutical are jointly carrying out research on the application of new drug clinical trial, so as to promote the project to the clinical trial stage as soon as possible. EU billion health previously reported the cooperation between British silicon intelligence and Fosun medicine. The two sides used artificial intelligence to drive drug research and development for four designated targets, and jointly developed the qpctl project of British silicon intelligence. At that time, the down payment of this cooperation was as high as US $13 million, setting a new record for the down payment of China's AI pharmaceutical cooperation transaction. Ism004-1057d is the first preclinical candidate compound developed by British silicon intelligence for the cooperative project. It is a potential global first small molecule inhibitor targeting qpctl targets. Qpctl plays a key role in the formation of pyroglutamate on CD47. This modification is CD47 and ligand SIRP α Necessary for interaction. CD47 is a glycoprotein widely expressed on the surface of many kinds of cancer cells α Interaction, releasing "don't eat me" signals to protect tumor cells from the surveillance of the natural immune system. Qpctl small molecule inhibitor can simulate the therapeutic effect of CD47 antibody and achieve the anti-tumor effect by blocking the signal.